A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation
Completed
Pfizer
Phase 3
2005-02-01
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given
for a twelve week treatment period in comparison with placebo for smoking cessation.
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Completed
Pfizer
Phase 3
2003-05-01
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given
for a twelve week treatment period in comparison with placebo and Zyban for smoking
cessation.
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
Completed
Pfizer
Phase 3
2003-10-01
The primary purpose of this study is to obtain safety information on cigarette smokers
treated with 52 weeks of varenicline regardless of smoking status.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
